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INTRODUCTION
Diabetes mellitus (DM) is a global non communicable 
disease. It is estimated to affect around 285 million individuals 
worldwide [1]. This disorder is associated with various factors 
that may have a pathogenic role in its development. One of 
these factors is the deficiency of vitamin D [2,3]. Various 
clinical studies have reported a positive correlation between 
the level of the circulating 25-hydroxy vitamin D (25(OH)D) 
and insulin sensitivity, thus the deficiency of vitamin D may 
predispose to the altered insulin sensitivity, hyperglycemia 
and type 2 DM [4]. There is also evidence that vitamin D 
deficiency may be associated with the manifestations of 
metabolic syndrome, namely dyslipidemia, hyperglycemia, 
hypertension and obesity [5]. Likewise, the association 
of reduced levels of vitamin D and the risk factors leading 
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to cardiac diseases may denote the potential extra skeletal 
functions of this sterol hormone [6, 7]. The association 
between obesity and increased adipose tissues is thought to 
be the key factor for all the previous disorders. This is thought 
to be mediated, at least partially, through the reducing effect 
of adipose tissue on vitamin D level by increased expression 
of vitamin D metabolizing enzymes such as 25-hydroxylase 
CYP2J2, CYP27B1, and CYP24 [8-10]. 
The mechanism of vitamin D function includes binding 
of its active metabolite 1,25-hydroxy vitamin D with vitamin 
D receptor (VDR) [11]. The VDR receptor belongs to 
steroid/thyroid hormone family of receptors and it functions 
as a transcriptional activator of many genes [12]. Single 
nucleotide polymorphisms (SNPs) in the VDR gene can 
affect the activity of the VDR that have been associated with 
various metabolic disorders [13-15]. VDR gene is located on 
chromosome 12q and there is more than 470 reported SNPs 
that can be considered as candidates for various disease risks 
[16]. An important VDR SNP includes the rs10735810/
rs2228570 (FokI) situated in exon 2. There are also three SNPs 
in linkage disequilibrium, namely rs1544410 (BsmI) located 
in intron 8, rs731236 (TaqI), and rs7975232 (ApaI), the last 
being a SNP located in exon 9 and intron 9 [17, 18]. Since 
there are insufficient data on the association of VDR gene 
polymorphism with type 2 DM and various components of 
metabolic syndrome among Egyptian patients, therefore the 
aim of this piece of research was to investigate the association 
of different SNPs of VDR genes, namely FokI, BsmI, ApaI, 
and TaqI with different components of metabolic syndrome 
and type 2 DM among a cohort of Egyptian patients.
MATERIALS AND METHODS
Study design
The study was conducted at Mansoura University Hospital 
from July 2017 till July 2018. The study is a case –control 
study. Subjects included in the study were divided into 
three groups. Group 1 included patients with type 2 DM as 
defined by the World Health Organization criteria having 
fasting blood glucose level 126 mg/dl or more, and/or 2h 
postprandial blood glucose level 200 mg/dl or more [19]. 
Exclusion criteria included: the presence of chronic illnesses 
that potentially alter vitamin D metabolism, pregnant or 
breastfeeding women, and the use of any variant of vitamin 
D supplements. The second group included patients with 
evidence of metabolic syndrome with minimum 3 of 5 of 
the following criteria: waist circumference equals 102 cm or 
more in men, and 88 cm or more in women; elevated fasting 
blood glucose above 110 mg/dl; elevated triglycerides above 
150 mg/dl; reduced HDL-cholesterol below 40 g/dl for men 
and below 50 mg/dl for women and elevated systolic blood 
pressure above 130 mmHg or diastolic blood pressure above 
85 mmHg [20]. In addition, one hundred healthy subjects 
with age match were enrolled as control group. All included 
subjects were also evaluated by clinical examinations. The 
study was approved by Mansoura University Faculty of 
Medicine Ethical Committee and was conducted according 
to the regulations of Declaration of Helsinki regarding 
conducting clinical research on human subjects. An informed 
written consent was obtained from each participant. 
Biochemical studies
From each subject 10 ml blood sample was withdrawn and 
divided into two aliquots: one with EDTA and the other was 
left plain. From the plain tubes, sera were separated and 
subjected to full biochemical study of total triglycerides, 
total cholesterol, HDL-cholesterol, fasting and post prandial 
blood glucose levels using commercially available assay kits. 
Total calcium was measured by Dialab 450 autoanalyzer and 
ionized calcium by GEM premier 3500 analyzer (Boston, 
SN:10090790). The total serum 25(OH)D was measured 
by ELISA kits (Calbiotech, CA, USA) according to the 
manufacturer's instructions.
Genotyping of VDR polymorphism
Blood samples on EDTA were subjected to leucocytes 
isolation by Ficoll gradient method (Sigma-Aldrich, St. 
Louis, MO, USA). DNA was extracted by the use of DNA
mini extract kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. The presence of the VDR 
FokI (rs2228570), BsmI (rs1544410), ApaI (rs7975232) and 
TaqI (rs731236) SNPs was identified by polymerase chain 
reaction-restriction fragment length polymorphism (PCR–
RFLP) according to the manufacturer’s instructions (New 
England BioLabs, Ipswich, USA). Restriction fragment size 
analysis was performed by visualization of digested PCR 
product by 2% agarose gel electrophoresis and ethidium 
bromide staining. Primer sequences and conditions for 
PCR–RFLP analyses are presented in Table 1. The presence 
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of the FokI, BsmI, ApaI and TaqI polymorphisms was 
confirmed by repeated PCR–RFLP analysis. The details of 
the amplification procedures were previously described [21, 
22].
Statistical analysis
Statistical analysis was performed by SPSS 16.0 software 
(SPSS Inc., Chicago, IL, USA). Data are presented as mean ± 
standard deviation (SD). Multiple or pair-wise comparison 
between means was done as appropriate by using one-way 
ANOVA or the paired t-test. The chi-square was used for 
pair-wise comparison between genotypes proportions. 
Pearson's correlation coefficient was used to calculate 
correlations between variables. Statistical significance was 
assumed when P values are ≤0.05.
RESULTS
The study included three groups, the first group included 
78 diabetic patients with mean age 45.4± 8.9 years mainly 
females (57.7%). The second group included 72 patients with 
criteria indicating that they had metabolic syndrome with 
mean age 44.5±6.9 years. They were mainly females (54.2%). 
The third group included 100 healthy control subjects with 
mean age 43.0±5.6 years and equal gender distribution. Table 
2 summarizes the demographic, clinical and laboratory 
findings of the studied groups. As shown in Table 2, there 
was statistically significant decrease in the levels of total 
calcium and 25(OH)D in diabetic patients and patients with 
metabolic syndrome as compared to healthy control subjects 
(P≤0.001). Additionally, there were significant elevated 
levels of total cholesterol, triglycerides, fasting blood glucose 
Table 1. Genetic polymorphisms primers, restriction endonuclease enzymes and sequences
FokI
polymorphism
Forward: 
5´- AGCTGGCCCTGGCACTGACTCTG-
GCTCT-3´ 
Reverse: 
5´- ATGGAAACACCTTGCTTCTTCTC-
CCTC -3´
FokI 
restriction 
enzyme
The wild type homozygote FF-270 bp 
heterozygote (Ff-270, 210 and 60 bp) 
and mutant homozygote (ff-210 and 60 
bp)
BsmI
polymorphism
Forward: 
5´- CAACCAAGACTACAAGTACCGCGT-
CAGTGA-3´
Reverse: 
5´-AACCAGCGGGAAGAGGTCAAGGG 
-3´
BsmI 
restriction 
enzyme
The wild type homozygote (BB-820 bp), 
heterozygote (Bb-820, 650 and 170 bp) 
and mutant homozygote (bb-650 and 
170 bp
ApaI 
polymorphism
Forward: 
5´- CAGAGCATGGACAGG GAGCAA-3´ 
Reverse: 
5´- GCAACTCCTCATGGCTGAGGTCTC 
-3´
ApaI 
restriction 
enzyme 
(Promega)
Absence of ApaI restriction site 
(2000bp) was assigned as a common 
allele A (wild-type allele) and presence 
of restriction site resulting in 1700 bp 
and 300bp fragments was assigned as 
infrequent allele a (mutant allele)
Presence of 2000, 1700 and 300 bp frag-
ments was assigned as heterozygotes 
(Aa). 
TaqI 
polymorphism
(S´-CAGAGCATGGACAGGGAG-
CAA-3´) and a reverse primer in exon 
9 (S´-GCAACTCCTCATGGCT GAG-
GTCTC-3´)
TaqI 
restriction 
endonuclease
Homozygous absence of the TaqI poly-
morphism results in two fragments of 
245 bp and 495 bp, while homozygous 
presence of the site results in three frag-
ments of 290,245, and 205 bp. Hetero-
zygotes exhibit fragments of   490, 290, 
245, and 205 bp
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and postprandial blood glucose levels in both two patients 
groups compared to healthy controls (P≤0.001).
Study of VDR genetic polymorphism had shown 
significant increase in the prevalence of Ff genotypes 
among diabetic patients and patients with manifestations of 
metabolic syndrome (P≤0.05, Table 3). In the study between 
25(OH)D levels and various biochemical parameters there 
was significant negative correlation between 25(OH)
D and total cholesterol, triglyceride, fasting and post 
prandial blood glucose levels (P≤0.001). Likewise, there 
was significant negative correlation between 25(OH)D and 
both waist circumference (and body-mass index [BMI], data 
not shown) and diastolic blood pressure (P≤0.001). On the 
contrary, there was significant positive correlation between 
25(OH)D and total calcium level (P≤0.001, Table 4).
As shown in Table 5, the study of the association between 
FokI genotypes and clinical and laboratory findings among 
both diabetic patients and patients with with metabolic 
syndrome had revealed significant correlation between 
decreased calcium, HDL-cholesterol and 25(OH)D levels 
and Ff genotype (P≤0.001, P≤0.05, P≤0.05 respectively). 
There were also significant increase in the risk factors 
associated with metabolic syndrome such as total cholesterol 
Table 2. Demographic, clinical and laboratory findings of the studied groups
Control  
(n=100)
Diabetic patients 
(n=78)
Patients with metabolic 
syndrome (n=72)
Gender 
Male
Female
50 (50%)
50 (50%)
33 (42.3%)
45 (57.7%)
33 (45.8%)
39 (54.2%)
Age 43.0 ± 5.6 45.4 ± 8.4 44.5 ± 6.9
Waist circumference (cm) 91.8 ± 6.4 112.4 ± 5.5‡ 90.1 ± 5.3*
Systolic blood pressure (mmHg) 108.7 ± 3.79 116.9 ± 6.1‡ 106.5 ± 4.15†
Diastolic blood pressure (mmHg) 75.7 ± 4.1 85.6 ± 4.07‡ 77.2 ± 3.13*
Total calcium (mg/dl) 9.5 ± 0.42 8.2 ± 0.57‡ 8.3 ± 0.64‡
Ionized calcium (mg/dl) 4.1 ± 0.17 4.0 ± 0.12† 4.05 ± 0.17*
25(OH)D (nmol/l) 140.0 ± 4.1 71.8 ± 3.6‡ 71.0 ± 4.1‡
Total cholesterol (mg/dl) 182.7 ± 6.7 265.5 ± 30.1‡ 181.7 ± 11.0
HDL-cholesterol (mg/dl) 53.9 ± 1.5 40.8 ± 4.4‡ 52.3 ± 2.4*
Triglycerides (mg/dl) 122.9 ± 5.3 232.1 ± 47.3‡ 173.0 ± 12.7‡
Fasting blood glucose (mg/dl) 103.0 ± 6.3 223.0 ± 38.6‡ 125.2 ± 2.01‡
Post prandial glucose (mg/dl) 112.5 ± 5.3 275.3 ± 37.6‡ 129.5 ± 2.5‡
Data are shown as mean ± SD. Significance levels: *P≤0.05, †P≤0.01, ‡P≤0.001 vs control group (Paired t-test).
Table 3. Genetic polymorphism of VDR among the 
studied groups
VDR 
Polymorphism
Control  
(n=100)
Diabetic 
patients 
(n=78)
Patients with 
metabolic 
syndrome 
(n=72)
BsmI
BB
Bb
bb
20 (20%)
30 (30%)
50 (50%)
33 (42.3%)†
39 (50%)*
6 (7.7%)‡
27 (37.5%)*
24 (33.3%)
21 (29.2%)†
ApaI
AA
Aa
aa
50 (50%)
20 (20%)
30 (30%)
21(26.9%)‡
45 (57.7%)‡
12 (15.4%)‡
18 (25%)‡
45 (62.5%)‡
9 (12.5%)‡
FokI
FF
Ff
ff
60 (60%)
20 (20%)
20 (20%)
18 (23.1%)‡
33 (42.3%)†
27 (34.6%)*
27 (37.5%)†
42 (58.3%)‡
3 (4.2%)‡
TaqI
TT
Tt
tt
60 (60%)
30 (30%)
10 (10%)
36 (46.2%)‡
21 (26.9%)
21 (26.9%)†
30 (41.7%)‡
27 (37.5%)
15 (20.8%)*
Data are shown as number and percentage. Significance 
levels: *P≤0.05, †P≤0.01, ‡P≤0.001 vs control group (chi-
square test for pair-wise proportions).
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(P≤0.001), postprandial blood glucose level (P≤0.001), 
triglycerides (P≤0.001), diastolic blood pressure (P≤0.05), 
and waist circumference (P≤0.001). Other genotypes of 
VDR had no significant association with any of the clinical 
or laboratory findings in the patients (data not shown).
DISCUSSION
There is evidence that VDR genotype may affect insulin action 
by regulating its secretion and resistance to its action [23]. 
Study of VDR genetic polymorphism had shown significant 
increase in the prevalence of Ff genotypes among diabetic 
patients and patients with signs of metabolic syndrome. 
Similar results were reported previously supporting those 
genotypes alleles in FokI gene of VDR can be associated 
more frequently in diabetic patients [24-27]. On contrary 
to our results, previous results on Egyptian patients with 
type 2 DM and metabolic syndrome revealed more frequent 
association of FF genotypes among those patients [28]. 
Also, previous reports had contradictory results about the 
association of polymorphism of VDR genres FokI, ApaI, 
BsmI and TaqI and risk of type 2 DM [29]. The reason for 
the discrepancy among the results may reflect the genetic 
differences in the studied populations and the interaction 
with other environmental factors predisposing to type 2 DM. 
Although mechanistically unclear, it has been suggested that 
both environmental and genetic factors seem to be involved 
in type 2 DM development [4].
There were significant associations between Ff VDR 
genotype and BMI (P≤0.01), and waist circumference 
(P≤0.001). Polymorphisms in the VDR gene have been linked 
with the increased susceptibility to obesity in subjects with 
type 2 DM [30-32]. Moreover, the results of the present study 
demonstrates significant association between Ff genotype of 
VDR and both elevated lipid parameters and diastolic blood 
Table 4. Correlation between 25(OH)D level with various 
biochemical and clinical findings
25(OH)D
Waist circumference r = - 0.5‡
Total calcium r = 0.6‡
Total cholesterol r = - 0.5‡
Triglycerides r = - 0.6‡
Systolic blood pressure r = - 0.1
Diastolic blood pressure r = - 0.5‡
Fasting blood glucose r = - 0.5‡
Postprandial glucose r = - 0.6‡
Significance levels: ‡P≤0.001 of Pearson's correlation 
coefficient.
Table 5. Association of genetic FokI polymorphism with various clinical and biochemical findings in both diabetic patients 
and patients with metabolic syndrome collectively
FokI polymorphism
FF  (n=45) Ff (n=75) ff (n=30)
Waist circumference (cm) 98.90± 10.5† 105.00± 12.4† 98.7 ± 2.4†
Systolic blood pressure (mmHg) 111.38± 6.6 112.8± 7.2 110.7 ± 8.0
Diastolic blood pressure (mmHg) 78.6± 6.4* 98.7± 13.0* 84.1 ± 6.2*
Total calcium (mg/dl) 8.8 ± 0.67* 8.2 ± 0.71* 8.5 ± 0.74*
Ionized calcium (mg/dl) 4.08 ± 15 4.01 ± .15 4.04 ± 17
25(OH)D (nmol/l) 91.5 ± 31.4* 83.0 ± 26.6* 73.02 ± 19.2*
Total cholesterol (mg/dl) 208.38 ± 45.7‡ 268.7 ± 45.5‡ 225.7 ± 38.7‡
HDL-cholesterol (mg/dl) 49.9 ± 5.37† 47.4 ± 7.5† 33.0 ± 6.1†
Triglycerides (mg/dl) 169.1 ± 41.4‡ 205.4 ± 58.2‡ 200.0 ± 52.7‡
Fasting blood glucose (mg/dl) 169.9 ± 60.6 192.7 ± 39.9 188.4 ± 54.4
Post prandial glucose (mg/dl) 197.8 ± 73.49‡ 235.7 ± 69.2‡ 225.5 ± 56.3‡
Data are shown as mean ± SD. Significance levels: *P≤0.05, †P≤0.01, ‡P≤0.001 (ANOVA).
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pressure. As known, the gene for VDR is also expressed 
on different tissues and mediates the action of vitamin D. 
Previous studies have reported the association of FokI VDR 
polymorphism with altered lipid profile [15]. It has been also 
reported that lower serum 25(OH)D may be associated with 
higher lipid parameters in diabetic patients. The present 
study provides a supportive evidence for this  relation as 
there was significant negative correlation between 25(OH)
D and both total cholesterol and triglyceride levels in both 
diabetic patients and patients with metabolic syndrome.
An explanations for such finding may include the 
increased secretion of parathyroid hormone secondary to 
declining levels of vitamin D.  The reduced vitamin D level 
is associated with decrease in intestinal calcium absorption 
with the resultant increase in parathyroid hormone secretion 
and subsequent acceleration of lipolysis [33]. Likewise, the 
reduced vitamin D level together with decreased intestinal 
calcium absorption can lead to increase in the hepatic 
triglyceride formation and secretion [34]. Moreover, the 
reduced vitamin D level decreases insulin secretion and 
insulin sensitivity that affects lipid metabolism [35].
One remarkable finding of the present study was to find 
a negative correlation between BMI and waist circumference 
and vitamin D level. In line with this observation, some 
previous studies have also reported correlation between 
decreased vitamin D levels and increase in BMI and waist 
circumference [36-38]. Also between vitamin D deficiency 
and increase of body fat [39, 40]. 
Vitamin D deficiency has been reported as a risk factor 
for various diseases such as osteoporosis, autoimmune 
diseases, various types of cancer, and cardiovascular diseases 
[41-44]. This association can be attributed to the common 
etiology of both obesity and reduced vitamin D due to 
reduced outdoor exercise. However, the results concerning 
this association had shown variations [45, 46]. Thus the 
nature of this association has to be fully investigated to 
understand this intimate orchestration as central adiposity 
is a key driver in the development of metabolic syndrome 
as well as cardiovascular disorders [47]. The association 
of reduced vitamin D level with increased diastolic blood 
pressure may be attributed to the vitamin D effects on lipid 
profile [48, 49]. 
There was significant negative correlation between 
25(OH)D and both fasting and post-prandial blood glucose 
levels. There is evidence that supports an effect of vitamin 
D on multiple levels of insulin release and action. Insulin 
release has been shown to be low in vitamin D-deficient rats 
and is enhanced by treatment with 1,25(OH)D [50, 51]. This 
may be attributed to the  complex effects of vitamin D on 
protein synthesis and/or increased conversion of pro-insulin 
to insulin [52]. 
In conclusion, the data obtained in this study show that 
the genetic polymorphism of vitamin D receptor might 
play a role in the development of type 2 DM and metabolic 
syndrome. Moreover, the serum level of 25(OH)D appears 
to have negative association with lipogram parameters such 
as total cholesterol and triglycerides. Despite the limitations 
of this study, we think this little piece of research might 
provide useful information on the asociation between 
VDR polymorphism and the risk of type 2 DM and/or 
metabolic syndrome in a sample of Egyptian patients. Larger 
multicenter studies with longer duration would be indeed 
more useful to consider limitations of data in hand and their 
context in comparison with those of other similar studies.
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